Cohance Lifesciences Limited — Important, 27-03-2025: Updates

Suven Pharmaceuticals Limited has announced the approval of a Scheme of Amalgamation by the Hon'ble National Company Law Tribunal (NCLT), which will see Cohance Lifesciences Limited merge into Suven. This Scheme aims to create a leading Contract Development and Manufacturing Organization (CDMO) in India, enhancing operational scale and broadening customer relationships. The merger will facilitate access to niche chemistry capabilities and state-of-the-art Good Manufacturing Practices (GMP) facilities, potentially driving sales and improving margins. The effective date of the merger will be determined after fulfilling all necessary conditions, including regulatory approvals. This development positions Suven for significant growth opportunities as a larger entity, warranting close observation from investors. The company will communicate the effective date to the stock exchanges once all prerequisites are cleared.